<DOC>
	<DOCNO>NCT00005607</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic recurrent cancer stomach esophagus .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Recurrent Cancer Stomach Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient metastatic recurrent adenocarcinoma stomach gastroesophageal junction treat irinotecan , fluorouracil , leucovorin calcium . II . Determine qualitative quantitative toxicity , reversibility toxicity , regimen patient population . OUTLINE : Patients receive irinotecan IV 90 minute , leucovorin calcium IV 15 minute , fluorouracil IV weekly 4 week follow 2 week rest . Treatment continue every 6 week absence unacceptable toxicity disease progression . Patients follow 30 day , death . PROJECTED ACCRUAL : A total 18-37 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent adenocarcinoma stomach gastroesophageal junction Bidimensionally measurable evaluable disease Mediastinal hilar lymph node assess CT MRI scan must least 2 cm diameter consider measurable Must curable combination chemotherapy radiotherapy No brain metastases No osseous metastasis site disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal No known Gilbert 's syndrome Renal : Creatinine great 1.5 mg/dL Calcium great 12 mg/dL No symptomatic hypercalcemia treatment Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history seizures No serious concurrent infection nonmalignant medical illness uncontrolled whose control may jeopardize study complication No psychiatric disorder would preclude study compliance No active malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No uncontrolled diabetes mellitus ( i.e. , random blood sugar le 250 mg ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy metastatic disease No concurrent immunotherapy Chemotherapy : See Disease Characteristics No prior chemotherapy metastatic disease No prior radiosensitizing chemotherapy metastatic setting At least 6 month since prior adjuvant therapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radiotherapy major bone marrow contain area ( e.g. , pelvis , lumbar spine ) No prior radiotherapy evaluable lesion No concurrent radiotherapy Surgery : At least 1 week since minor surgery 3 week since major surgery recover Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis No concurrent prochlorperazine day irinotecan administration No concurrent medication except analgesic , chronic treatment concurrent medical condition , agent require life threaten medical problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>